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RESEARCH LETTER
Effects of Endogenous Angiotensin II 
on Abdominal Aortic Aneurysms and 
Atherosclerosis in Angiotensin II– Infused 
Mice
Masayoshi Kukida , MD, PhD*; Hisashi Sawada , MD, PhD*; Satoko Ohno- Urabe, MD, PhD;  
Deborah A. Howatt, BS; Jessica J. Moorleghen, BS; Marko Poglitsch, PhD; Alan Daugherty , PhD, DSc;  
Hong S. Lu , MD, PhD
Angiotensin II (Ang II) is a major effector of the renin- angiotensin system and is important in regulat-ing vascular function. Infusion of Ang II induces 
abdominal aortic aneurysms (AAA) and exacerbates 
atherosclerosis in hypercholesterolemic mice. In Ang 
II– infused normocholesterolemic rats, endogenous 
Ang II production is maintained in kidney.1 However, 
the effects of endogenous Ang II on AAA and athero-
sclerosis during Ang II infusion in hypercholesterolemic 
mice have not been studied.
Detailed methods and results are available in 
bioRxiv (https://doi.org/10.1101/2020.11.18.377416). All 
animal experiments were approved by the University of 
Kentucky Institutional Animal Care and Use Committee. 
SigmaPlot version 14.0 (Systat Software Inc) was used 
for statistical analyses. Since either normality (Shapiro- 
Wilk test) or homogeneous variation (Brown- Forsythe 
test) was not confirmed, all data were analyzed using 
nonparametric analyses. Statistical tests might be 
underpowered.
Our previous studies revealed that liver- specific de-
letion of angiotensinogen, the sole precursor of Ang 
II, reduced atherosclerotic lesion area with decreases 
of Ang II concentrations in kidney but not plasma.2 
In addition, inhibition of angiotensinogen uptake into 
renal proximal tubular cells ameliorated atherosclero-
sis development.3 These results indicate an important 
role of renal Ang II in atherosclerosis formation. In an 
initial study, either vehicle or murine Ang II (1000 ng/kg 
per minute) was infused into male C57BL/6J mice for 
7 days via osmotic pumps (Alzet model 2001, Durect 
Corporation). Then, we determined concentrations of 
angiotensin peptides in plasma and kidney by liquid 
chromatography– tandem mass spectrometry. Plasma 
Ang II concentrations were not altered by Ang II infusion 
(Figure  [A]). Consistent with a previous report,1 renal 
Ang II concentrations were significantly higher in Ang 
II– infused mice than in vehicle- infused mice (Figure [A]). 
Since Ang II is metabolized to Ang III and Ang(1– 7) and 
these peptides may contribute to the pathophysiology 
of atherosclerosis,4 we assessed Ang III and Ang(1– 7) 
concentrations in Ang II– infused mice. Ang(1– 7) was 
not detectable in plasma and kidney from either vehi-
cle- or Ang II– infused mice, and Ang III concentrations 
were not statistically different in plasma and kidney be-
tween infusions (Figure [B]). These results indicate that 
exogenous Ang II does not affect productions of major 
Ang II metabolites.
Since Ang I is the direct substrate of Ang II, we 
measured plasma and renal Ang I concentrations 
to evaluate the production of Ang II. Ang II infusion 
decreased Ang I concentrations in both plasma and 
kidney (Figure  [C]). However, Ang II– induced reduc-
tion of Ang I concentrations was modest in kidney 
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compared with those in plasma (96% in plasma ver-
sus 62% in kidney, P<0.05 by Mann- Whitney U test) 
(Figure  [C]), indicating persistent renal Ang II pro-
duction during Ang II infusion. We next investigated 
the presence of endogenous Ang II in kidney of Ang 
II– infused mice. Bovine Ang II differs from murine 
Ang II (Asp- Arg- Val- Tyr- Ile- His- Pro- Phe) in the fifth 
amino acid being Val (Asp- Arg- Val- Tyr- Val- His- Pro- 
Phe). The 1 amino acid difference results in a mass 
difference that enabled distinction between bovine 
and murine Ang II by liquid chromatography– tandem 
mass spectrometry as exogenous and endogenous 
sources, respectively, in bovine Ang II– infused mice. 
Bovine Ang II exerted comparable effects to murine 
Ang II on AAA and atherosclerosis formation in male 
low- density lipoprotein receptor– deficient mice fed a 
Western diet (Figure  [D]), indicating that bovine Ang 
II infusion mimicked murine Ang II infusion– induced 
renin- angiotensin system regulation in mice. As ex-
pected, bovine Ang II infusion increased exogenous 
Ang II concentrations in kidney (Figure [E]). The me-
dian of renal endogenous Ang II concentrations in 
vehicle- infused mice was 843  pg/g (interquartile 
range, 669– 1179 pg/g) (Figure [E]). Ang II infusion re-
duced endogenous Ang II concentrations to 161 pg/g 
(interquartile range, 77– 235 pg/g). Endogenous Ang 
II was still detectable in mice with bovine Ang II in-
fusion. Alongside the presence of renal Ang I, these 
data support that intrarenal Ang II production is con-
tinued during Ang II infusion.
Figure. Contributions of angiotensin II (Ang II) to abdominal aortic aneurysms (AAA) and atherosclerosis in Ang II– infused 
mice.
Plasma and renal concentrations of (A) Ang II, (B) Ang III, and (C) Ang I in male C57BL/6J mice (8- to 10- weeks- old, The JAX # 
000664) infused with either vehicle (n=16) or murine Ang II (1000 ng/kg per minute, n=7) for 7 days. (D), Maximal external diameters of 
abdominal aorta and percent atherosclerotic lesion areas in male low- density lipoprotein receptor– deficient mice (LDLR−/−, 10- week- 
old; The JAX, stock # 002207) fed a Western diet and infused with vehicle (n=8), murine Ang II (mAng II, 1000 ng/kg per minute, n=9), 
or bovine Ang II (bAng II, 1000 ng/kg per minute, n=10). (E), Renal Ang II concentrations of exogenous and endogenous source in either 
vehicle (n=6) or bovine Ang II (1000 ng/kg per minute, n=7)– infused mice. (F), Aliskiren (25 mg/kg per day) suppressed atherosclerotic 
lesion size but not abdominal aortic dilatation in LDLR- deficient mice (8- week- old) with Ang II infusion for 4 weeks (vehicle, n=8; mAng 
II, n=16; Ang II+aliskiren, n=17). Angiotensin peptides were measured by liquid chromatography– tandem mass spectrometry. Data 
are presented as box plots drawn from the 25th to 75th percentiles with a line at the median. *P<0.05, **P<0.01, ***P<0.001 by Mann- 
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We next investigated whether inhibition of en-
dogenous Ang II production attenuated AAA and 
atherosclerosis formation during Ang II infusion. 
Angiotensin- converting enzyme inhibitors or direct 
renin inhibitors suppress endogenous Ang II pro-
duction. However, angiotensin- converting enzyme 
inhibitors target several other substrates such as 
bradykinin that may affect cardiovascular functions. 
To investigate the effects of endogenous Ang II on 
AAA and atherosclerosis formation, we administered 
aliskiren, a direct renin inhibitor, to inhibit endoge-
nous Ang II production into Ang II– infused mice. 
Murine Ang II (1000 ng/kg per minute) was infused 
into low- density lipoprotein receptor– deficient mice 
for 28  days that led to significant augmentation of 
AAA and atherosclerosis. On the basis of our pre-
vious study that aliskiren infusion of 25  mg/kg per 
day led to maximal inhibitory effects on endogenous 
Ang II production in mice,5 we used this infusion rate 
of aliskiren in this experiment. As expected, contin-
uous Ang II infusion induced AAA and augmented 
atherosclerotic lesions compared with vehicle infu-
sion (Figure  [F]). Aliskiren did not inhibit abdominal 
aortic expansion in Ang II– infused mice. Although 
atherosclerotic lesion size in aliskiren and Ang II– 
infused mice was larger than vehicle- infused mice, 
aliskiren reduced lesion size significantly, compared 
with Ang II infusion alone. These results support that 
AAA development was attributed to exogenous Ang 
II, whereas atherosclerosis was augmented by both 
endogenous and exogenous Ang II.
In conclusion, renal endogenous Ang II is present in 
Ang II– infused mice, and endogenous Ang II contrib-
utes to Ang II– mediated atherosclerosis, but not AAA, 
formation in hypercholesteremic mice.
While Ang II infusion accelerates atherosclerosis for-
mation and renal Ang II concentrations, there has not 
been a determination that the renal changes directly 
impact the vascular pathology. Proximal tubule cells 
(PTCs) contain angiotensinogen, renin and angiotensin- 
converting enzymes that are needed to generate Ang 
II.3 Ang II type 1a receptors, the determinant of Ang 
II– induced atherosclerosis, are also present in PTCs. 
Therefore, we hypothesize that Ang II production in 
PTCs augments atherosclerosis. To test this hypoth-
esis, mice are being developed with PTC- specific Ang 
II type 1a receptor genetic deficiency or PTC overex-
pression of human AGT and human renin.
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